Market Size and Growth Outlook
The Next Generation Sequencing market is projected to grow significantly, reaching over USD 48.08 billion by 2035, up from USD 12.33 billion in 2024. The market valued at USD 13.95 billion in 2025 and is anticipated to expand at a CAGR of 13.17% during the forecast period from 2025 to 2035.
Key Report Highlights
Next generation sequencing (NGS) is a rapid and high throughput technology used to analyse DNA and RNA sequences. It includes sequencing platforms, reagents and bioinformatics tools used in diagnostics, research and drug discovery. The NGS market is growing due to the rising demand for genomic testing in cancer and rare disease diagnosis, increasing investments in precision medicine and wider adoption of sequencing technologies in healthcare and research institutions. AI enhances next generation sequencing workflows by efficiently analysing large genomic datasets, identifying sequencing errors, low quality reads and inconsistencies in variant detection, thereby improving overall accuracy in genome and targeted sequencing. Machine learning tools support automated variant annotation, disease risk prediction and quality assessment of sequencing data, helping laboratories improve diagnostic precision and reduce analysis time in clinical and research settings.
The rising global incidence of cancer is increasing the demand for genomic profiling and molecular diagnostics as hospitals and oncology centers use sequencing technologies to identify mutations and support personalised cancer treatment. The growing adoption of liquid biopsy tests in oncology is increasing the demand for highly sensitive sequence technologies for cancer detecting, profiling and treatment monitoring through minimally invasive methods.
On the basis of offering, consumables dominated in 2024 with a 54.2% revenue share due to high demand for reagent kits, flow cells and sample preparation products, while platforms are expected to witness the fastest CAGR with increasing adoption of automated and high-throughput sequencing systems. By technology, targeted sequencing and resequencing accounted for the largest market share because they reduce data complexity, lower sequencing costs and support companion diagnostics for cancer and inherited disorders, meanwhile, Whole Genome Sequencing is projected to grow at the fastest rate due to increasing genome mapping projects and advancements in bioinformatics tools. Based on workflow, the sequencing segment dominated the market as high-throughput systems improve sample processing speed, accuracy and diagnostic turnaround time, however, NGS data analysis is expected to record the highest CAGR because growing genomic data volumes are increasing the need for advanced bioinformatics and AI-powered analytics platforms. Based on application, oncology held the highest revenue share due to the rising adoption of genomic profiling, tumour mutation detection, targeted therapies and liquid biopsy testing in cancer care, while, reproductive health is expected to grow rapidly because of increasing use of non-invasive prenatal testing and carrier screening programs. By end user, academic and research institutes held the largest share due to growing genome research activities and government funding, whereas hospitals and clinics are expected to register the fastest CAGR with increasing adoption of precision medicine and routine genomic testing.
North America dominated the NGS market in 2024 with a 42.57% share, valued at USD 5.25 billion. The growth is driven by strong adoption of genomic testing, established reimbursement systems and genome research initiative in the US, which accounted for 86.4% of the regional market. Asia pacific is expected to witness the fastest growth during the forecast period due to rising investments in genome sequencing projects, precision medicine, oncology diagnostic and prenatal screening across China, India, Japan and South Korea. The European market is growing due to government funded genome mapping programs and increasing adoption of personalised medicine and routine genetic profiling in countries such as UK, Germany and France. Growth in Latin America is supported by rising cancer testing volumes and expansion of molecular diagnostics in Brazil and Mexico. The Middle East and Africa market is driven by healthcare modernization programs and increasing genomic research activities in countries such as UAE, Saudi Arabia and South Africa.
Next Generation Sequencing Market Trends
- Rising adoption of precision medicine is increasing the use of next generation sequencing for personalized treatment and genomic profiling.
- Growing demand for liquid biopsy testing is expanding the use of sequencing technologies in cancer detection and monitoring.
- Integration of AI and advanced bioinformatics tools is significantly improving variant analysis, enabling faster and more accurate interpretation of complex genetic data. This is helping clinicians identify disease-causing mutations more efficiently and improving diagnostic confidence.
- Increasing installation of high-throughput and automated sequencing platforms is enhancing laboratory efficiency and reducing turnaround time.
- Declining sequencing costs are making genomic technologies more affordable and accessible, which is supporting the wider adoption of whole genome sequencing as well as expanding the use of prenatal and carrier genetic testing across different populations.
List Of Key Players in Next Generation Sequencing Market
- Illumina Inc. – US
- Thermo Fisher Scientific Inc. – US
- BGI Genomics Co. Ltd. – China
- Agilent Technologies Inc. – US
- Pacific Biosciences of California Inc. – US
- Oxford Nanopore Technologies plc – UK
- QIAGEN N.V. – Germany
- Roche Sequencing Solutions Inc. – US
- PerkinElmer Inc. – US
- Eurofins Scientific SE – Luxembourg
Next Generation Sequencing Market Segmentation
The next generation sequencing market is segmented on the basis of offering, technology, workflow, application and end user:
Next Generation Sequencing Market Offering Outlook, Revenue (USD Billion) (2025-2035)
- Platform
- Sequencing
- Data Analysis
- Consumables
- Sequencing
- Data Analysis
Next Generation Sequencing Market Technology Outlook, Revenue (USD Billion) (2025-2035)
- WGS
- Whole Exome Sequencing
- Targeted Sequencing & Resequencing
- Sequencing
- Data Analysis
- Others
Next Generation Sequencing Market Workflow Outlook, Revenue (USD Billion) (2025-2035)
- Pre-Sequencing
- Nucleic Acid Extraction
- Library Preparation
- Sequencing
- NGS Data Analysis
- NGS Primary Data Analysis
- NGS Secondary Data Analysis
- NGS Tertiary Data Analysis
Next Generation Sequencing Market Application Outlook, Revenue (USD Billion) (2025-2035)
- Oncology
- Clinical Investigation
- Reproductive Health
- HLA Typing/Immune System Monitoring
- Metagenomics, Epidemiology & Drug Development
- Agrigenomics & Forensics
- Consumer Genomics
Next Generation Sequencing Market End User Outlook, Revenue (USD Billion) (2025-2035)
- Academic and Research Institutes
- Hospitals and Clinics
- Pharmaceutical and Biotechnology Companies
- Other End Users
Next Generation Sequencing Market Regional Outlook, Revenue (USD Billion) (2025-2035)
- North America
- Canada
- Mexico
- U.S.
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Europe
- Germany
- France
- UK
- Spain
- Russia
- Italy
- BENELUX
- Latin America
- Argentina
- Brazil
- Chile
- Middle East and Africa
- GCC
- Turkey
- South Africa